Suppr超能文献

通过毛细管微量采血和超高效液相色谱-串联质谱法测定碘海醇

Determination of iohexol by capillary blood microsampling and UHPLC-MS/MS.

作者信息

Ion Valentin, Legoff Caroline, Cavalier Etienne, Delanaye Pierre, Servais Anne-Catherine, Muntean Daniela-Lucia, Fillet Marianne

机构信息

Laboratory for the Analysis of Medicines (LAM), Center for Interdisciplinary Research on Medicines (CIRM), University of Liège, Liège, Belgium.

Analytical Chemistry and Drug Analysis Department, Faculty of Pharmacy, University of Medicine Pharmacy Science and Technology from Tîrgu Mureș, 540139, Tîrgu Mureș, Romania.

出版信息

J Pharm Anal. 2019 Aug;9(4):259-265. doi: 10.1016/j.jpha.2019.06.003. Epub 2019 Jun 27.

Abstract

One of the most important tools used to evaluate kidney function in the context of chronic kidney disease or other renal function related pathologies is the exploration of glomerular filtration rate (GFR). Iohexol is up to this moment a good candidate molecule for the GFR assessment since it exhibits minimum protein binding rates and minimum extra-renal clearance, being neither secreted nor reabsorbed at the tubular level. This study proposes and evaluates a new LC-MS/MS method for the iohexol determination from capillary blood, prelevated using volumetric absorbative microsampling (VAMS) systems. As an alternative to VAMS, a brand new HemaPEN device for micro-prelevation was also tested. A new high throughput sample preparation protocol adapted for iohexol quantification from whole blood VAMS samples was developed. The medium term stability study of iohexol in dried whole blood VAMS samples that was conducted showed a good stability of this molecule for up to 12 days. By collecting only 10 μL of blood, iohexol can be analyzed from dried whole blood VAMS samples for concentration ranges between 1 and 250 μg/mL. Due to the analyte stability in VAMS for up to 12 days, this approach might be successfully applied for GFR assessment for clinical cases allowing minimum invasiveness and even delayed analysis.

摘要

在慢性肾脏病或其他与肾功能相关的病理情况下,用于评估肾功能的最重要工具之一是肾小球滤过率(GFR)的测定。到目前为止,碘海醇是GFR评估的良好候选分子,因为它的蛋白结合率最低,肾外清除率最低,在肾小管水平既不分泌也不重吸收。本研究提出并评估了一种新的液相色谱 - 串联质谱法,用于从使用体积吸收微量采样(VAMS)系统采集的毛细血管血中测定碘海醇。作为VAMS的替代方法,还测试了一种全新的用于微量采血的HemaPEN设备。开发了一种适用于从全血VAMS样品中定量碘海醇的新的高通量样品制备方案。对干燥全血VAMS样品中碘海醇进行的中期稳定性研究表明,该分子在长达12天内具有良好的稳定性。仅采集10μL血液,就可以从干燥全血VAMS样品中分析碘海醇,浓度范围为1至250μg/mL。由于分析物在VAMS中长达12天的稳定性,这种方法可能成功应用于临床病例的GFR评估,具有最小的侵入性甚至允许延迟分析。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/229f/6702420/b5cdeac165d5/fx1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验